Lantern Pharma and Bielefeld University Collaborate on Breakthrough Antibody Drug Conjugates (ADCs) using AI Platform RADR®
Lantern Pharma has announced a collaboration with Bielefeld University to develop innovative antibody-drug conjugates (ADCs) using their AI platform, RADR®. This collaboration will be led by Professor Norbert Sewald, an expert in cryptophycin synthesis and ADC development, and the coordinator of the "Magicbullet::reloaded" consortium.
The goal of the collaboration is to leverage RADR®'s AI capabilities and Professor Sewald's expertise to rapidly develop novel ADCs linked to cryptophycins. Cryptophycins are potent antitumor molecules known for their effectiveness at ultra-low concentrations. The synthesized cryptophycin-ADCs will be tested on various cancer cell lines, with initial results expected in 2023.
The collaboration aims to pave the way for next-generation ADCs and other drug conjugates designed using AI. By utilizing RADR®'s AI ADC module, Lantern Pharma aims to develop ADCs with higher therapeutic efficacy, faster development timelines, and reduced costs.
The global ADC market is currently valued at over $4.0 billion and is projected to reach $14.0 billion by 2027. Lantern Pharma plans to leverage their AI ADC development module integrated into RADR® to launch multiple ADCs using cryptophycins or other promising payloads. The company also intends to collaborate with academic and commercial partners to develop additional ADC candidates for targeted clinical trials.
As part of the collaboration, Bielefeld University grants Lantern Pharma an exclusive worldwide option to license intellectual property related to the collaboration and any IP generated from it. The partnership between Lantern Pharma and Bielefeld University holds promise for advancing the field of ADCs and revolutionizing the development of effective and targeted therapies for advanced cancers.
